Le Lézard
Classified in: Health
Subject: FDA

OssDsign Receives US FDA Clearance for Cranial PSI Accessories - Strengthening Business Position in the US

STOCKHOLM, Oct. 14, 2019 /PRNewswire/ -- OssDsign AB (publ) ("OssDsign" or the "Company") today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance (K190523) to market OssDsign Cranial PSI Accessories in the US. The cleared products are a set of 3D-printed, patient specific accessory devices designed to support and expand clinical use of OssDsign's patient specific cranioplasty implant already cleared by the FDA. The accessories are designed to make cranial reconstructions safer and easier and to enable new solutions for patients in need of complex cranial reconstructions.

OssDsign is a provider of patient specific implants and surgical solutions for cranial and facial reconstruction. As part of market expansion efforts, the company has developed an innovative set of accessory products, ranging from anatomical models to surgical guides and intraoperative implant trials. The accessories are designed to make cranial reconstructions safer and easier and to enable new solutions for patients in need of complex cranial reconstructions.

The new FDA clearance will enable OssDsign to continue to drive growth in the US by gaining access to additional cohorts of patients with complex cranial defects. The new accessories, along with OssDsign's novel implant technology, will provide US neurosurgeons the possibility to remove bone tumors or otherwise diseased bony tissue and perform cranial reconstruction in a single stage procedure. One less surgical intervention can greatly reduce patient trauma while saving time and resources for hospitals.

Cranial PSI Accessories have already been available on the European market, and European neurosurgeons have successfully been able to treat patients for whom no viable surgical solution previously existed. An example from this patient category includes a unique case of near total cranial reconstruction treated with a complete surgical solution of OssDsign implants and accessories. The surgical procedure was made possible by the use of surgical guides, part of the OssDsign Accessories product range. The case is published in The Journal of Neurosurgery. https://thejns.org/abstract/journals/j-neurosurg/131/3/article-p735.xml?rskey=JO79ET&result=1

Anders Lundqvist, CEO of OssDsign says: "I think it's safe to say that we are the only company with the technology platform and clinical competence necessary to produce implant solutions suitable for some of these extremely complex cranial reconstructions. These accessory products combined with our novel implant technology fulfil an unmet medical need, enabling treatment of very complex patient groups. Involvement with these complex cases have also resulted in new innovations, IP and product development opportunities."

For further information, please contact:

Anders Lundqvist, CEO, OssDsign AB
Tel: +46-73-206-98-08
email: al@ossdsign.com

Certified Adviser

The Company's Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign

OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:




These press releases may also interest you

at 20:41
The Government of Alberta announced that it will begin forcibly switching 26,000 patients from their physician-chosen biologic medicines to government-chosen biosimilars beginning July 1st, 2020. These patients include 22,000 Albertans with diabetes,...

at 18:55
Schaumburg Dental Studio is hosting an annual toy drive just in time for the holidays. The respected dentists of Schaumburg Dental Studio invite their community to join them in collecting stockings for children in Lake County, IL. The toy drive will...

at 18:30
The human rights group Attorneys for the Rights of the Child (ARC) (http://www.arclaw.org) has today criticized a proposal to continue the so-called voluntary medical male circumcision (VMMC) program in Africa, though only on boys mostly 15 years of...

at 18:24
Canopy Growth Corporation, USA, LLC ("Canopy Growth" or the "Company") today announced the launch of First & Free ? a hemp-derived CBD product line offered in a variety of formats, including softgels, oil drops and creams. The products will be...

at 18:19
Below are experts from the ProfNet network who are available to discuss timely issues in your coverage area.   You can also submit a query to the hundreds of thousands of experts in our network ? it's easy and free. Just...

at 18:14
Amarin Corporation plc today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication and label expansion for VASCEPA® (icosapent ethyl) capsules. After more than a decade of development and testing, VASCEPA is now...

News published on 14 october 2019 at 03:11 and distributed by: